423 related articles for article (PubMed ID: 15915381)
1. [Update on therapy of invasive mycoses in hematology and oncology].
Maschmeyer G; Haas A; Böhme A
Dtsch Med Wochenschr; 2005 Jun; 130(22):1381-4. PubMed ID: 15915381
[No Abstract] [Full Text] [Related]
2. Use of newer antifungal therapies in clinical practice: what do the data tell us?
Perfect JR
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):15-23. PubMed ID: 15651178
[TBL] [Abstract][Full Text] [Related]
3. Management of invasive mycoses in hematology patients: current approaches.
Perfect JR
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):5-14. PubMed ID: 15651177
[TBL] [Abstract][Full Text] [Related]
4. Update on antifungal therapy.
Gigolashvili T
Cancer Pract; 1999; 7(3):157-9. PubMed ID: 10352080
[No Abstract] [Full Text] [Related]
5. [The future of antifungal agents].
Maesaki S
Rinsho Ketsueki; 2007 Jan; 48(1):26-35. PubMed ID: 17313074
[No Abstract] [Full Text] [Related]
6. Caspofungin versus liposomal amphotericin B for empirical therapy.
Danaher PJ
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675092
[No Abstract] [Full Text] [Related]
7. [New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin].
van 't Wout JW; Kuijper EJ; Verweij PE; Kullberg BJ
Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1679-84. PubMed ID: 15453120
[TBL] [Abstract][Full Text] [Related]
8. Antifungal therapy in patients with fever and neutropenia--more rational and less empirical?
Klastersky J
N Engl J Med; 2004 Sep; 351(14):1445-7. PubMed ID: 15459307
[No Abstract] [Full Text] [Related]
9. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
[TBL] [Abstract][Full Text] [Related]
10. [Cerebral aspergillosis in an HIV-infected patient: unsuccessful outcome despite combined antifungal therapy. ].
Gasch O; Fernández N; Ayats J; Santin M
Enferm Infecc Microbiol Clin; 2009 Mar; 27(3):193-4. PubMed ID: 19306722
[No Abstract] [Full Text] [Related]
11. Voriconazole for candidosis: an important addition?
Graybill JR
Lancet; 2005 Oct 22-28; 366(9495):1413-4. PubMed ID: 16243074
[No Abstract] [Full Text] [Related]
12. Combination antifungal therapy for invasive aspergillosis.
Cesaro S; Visintin G
Clin Infect Dis; 2005 Apr; 40(7):1073-5; author reply 1075-6. PubMed ID: 15825015
[No Abstract] [Full Text] [Related]
13. [symbol: see text]Caspofungin and [symbol: see text]voriconazole for fungal infections.
Drug Ther Bull; 2004 Jan; 42(1):5-8. PubMed ID: 14768298
[TBL] [Abstract][Full Text] [Related]
14. Fungal infections in solid organ transplantation.
Marik PE
Expert Opin Pharmacother; 2006 Feb; 7(3):297-305. PubMed ID: 16448324
[TBL] [Abstract][Full Text] [Related]
15. Systemic mycoses in the immunocompromised host: an update in antifungal therapy.
Kontoyiannis DP; Mantadakis E; Samonis G
J Hosp Infect; 2003 Apr; 53(4):243-58. PubMed ID: 12660121
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of concomitant pulmonary zygomycosis and aspergillosis with a combination of amphotericin B lipid complex, caspofungin, and voriconazole in a patient on immunosuppression for chronic graft-versus-host disease.
Verma A; Williams S; Trifilio S; Zembower T; Mehta J
Bone Marrow Transplant; 2004 May; 33(10):1065-6. PubMed ID: 15048146
[No Abstract] [Full Text] [Related]
17. Hope for patients with neoplastic disease and invasive fungal infections.
McLeroth P; Polsky B
J Support Oncol; 2005; 3(4):299-300. PubMed ID: 16092601
[No Abstract] [Full Text] [Related]
18. Caspofungin versus liposomal amphotericin B for empirical therapy.
Schneemann M; Imhof A
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675094
[No Abstract] [Full Text] [Related]
19. An update on the use of antifungal agents.
Martinez R
J Bras Pneumol; 2006; 32(5):449-60. PubMed ID: 17268750
[TBL] [Abstract][Full Text] [Related]
20. [Clinical development of antimycotics. Medical challenges].
Lipp HP
Pharm Unserer Zeit; 2003; 32(2):144-52. PubMed ID: 12677968
[No Abstract] [Full Text] [Related]
[Next] [New Search]
